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Abstract
Background—Northeastern states of the US show more progress in reducing colorectal cancer 
(CRC) incidence and mortality rates than Southern states, resulting in considerable disparities. We 
quantified how the disparities in CRC rates between Louisiana (Southern state) and New Jersey 
(Northeastern state) would be affected if differences in risk factors, screening and stage-specific 
CRC relative survival between states were eliminated.
Methods—We used the MISCAN-Colon microsimulation model to estimate age-adjusted CRC 
incidence and mortality rates in Louisiana from 1995-2009 assuming Louisiana had the same 1) 
smoking and obesity prevalence; 2) CRC screening uptake; 3) stage-specific CRC relative 
survival; and 4) a combination of all three, as observed in New Jersey.
Results—In 2009 the observed CRC incidence and mortality rates in Louisiana were 141.4 cases 
and 61.9 deaths per 100,000 individuals, respectively. With the same risk factors and screening as 
New Jersey, the CRC incidence rate in Louisiana was reduced by 3.5% and 15.2%. New Jersey's 
risk factors, screening and survival reduced the CRC mortality rate in Louisiana by 3.0%, 10.8%, 
and 17.4%, respectively. With all trends combined, the modeled rates per 100,000 individuals in 
Louisiana became lower than the observed rates in New Jersey for both incidence (116.4 versus 
130.0) and mortality (44.7 versus 55.8).
Conclusions—The disparities in CRC incidence and mortality rates between Louisiana and 
New Jersey could be eliminated if Louisiana could attain New Jersey levels of risk factors, 
screening and survival. Priority should be given to enabling Southern states to improve screening 
and survival rates.
Keywords
Colorectal cancer; screening; computer simulation; prevention and control
Corresponding author: S. Lucas Goede, MSc, Department of Public Health, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The 
Netherlands; phone: +31-10-7038459; fax: +31-10-7038474; s.goede@erasmusmc.nl. 
Conflicts of interest. None
HHS Public Access
Author manuscript
Cancer. Author manuscript; available in PMC 2016 October 15.
Published in final edited form as:














Colorectal cancer (CRC) is the second leading cause of cancer death in the United States 
(US). An estimated 132,700 CRC cases will be newly diagnosed and 49,700 persons will die 
of the disease in 2015.[1] While age-standardized CRC incidence and mortality rates have 
been decreasing in the Northeastern states of the US since the late 1970s/early 1980s, the 
decreases began later and were slower in the Southern states.[2] As a result, CRC incidence 
and mortality rates are now higher in Southern states than in Northeastern states, opposite to 
the patterns observed prior to 1980.[2]
Most cancer control plans and policies that affect cancer prevention and access to screening 
in the US are designed and implemented at the state level. The observed variation in CRC 
incidence and mortality trends between states provides important information for policy 
makers on the success of the implemented interventions and provides evidence that 
interventions in some states can be improved. Differences in risk factors, screening and 
treatment are the most likely candidates to explain the observed disparity in CRC incidence 
and mortality trends.[3] Screening has been hypothesized to be the most important driver.[2] 
However, the individual contributions of these factors to disparities have never been 
evaluated, and doing so could inform the design of future cancer control policies and 
interventions.
In this analysis, we determined to what extent improving risk factor prevalence, screening 
uptake and CRC relative survival could reduce observed disparities in CRC incidence and 
mortality rates between states. We chose Louisiana as an exemplary Southern state with 
unfavorable trends in CRC incidence and mortality, and New Jersey as an exemplary 
Northeastern state with more favorable trends, because for both states long term, high-
quality cancer registry data are available through the Surveillance Epidemiology and End 
Results (SEER) Program and the National Program of Cancer Registries (NPCR).
Methods
We used the MISCAN-Colon microsimulation model[4] of the Cancer Intervention and 
Surveillance Modeling Network (CISNET) to quantify how the disparity in observed CRC 
rates between Louisiana and New Jersey would be affected if Louisiana were to attain risk 
factor prevalence (i.e. smoking and obesity), screening uptake and stage-specific relative 
survival for CRC as observed in New Jersey. Stage-specific survival was used as a proxy for 
differences in treatment between states.
MISCAN-Colon Model
Supporting material 1 describes the MISCAN model. Briefly, the model simulates the life 
histories of a large population of individuals from birth to death and has a natural history 
component that tracks the progression of underlying colorectal disease in the absence of 
screening. As each simulated individual ages, there is a chance that one or more adenomas 
may develop depending on age, sex, race and individual risk. Adenomas can progress in size 
from small (≤5 mm) to medium (6-9 mm) to large (≥10 mm), and some may eventually 
become malignant. A preclinical (i.e., not yet detected) cancer has a chance of progressing 
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through stages I-IV and may be detected because of symptoms at any stage. With screening, 
adenomas and preclinical cancers may be detected depending on the sensitivity of the test 
and, for endoscopic tests, whether the lesion is within reach of the endoscope.
The natural history part of the model was calibrated to pre-screening data from autopsy 
studies and 1995 age-specific CRC incidence from the Louisiana Tumor Registry (main 
assumptions presented in Table 1).[5] We included only first primary cases. Autopsy only 
and death certificate only cases, as well as tumors of the appendix were excluded. The 
model uses state-specific all-cause mortality life tables from the Cancer Survival in Five 
Continents study (CONCORD).[10] Stage-specific relative survival following CRC 
diagnosis from 1995 to 2009 for Louisiana and New Jersey were obtained from SEER data 
(Supporting material 2).[6] The prevalence of smoking and obesity over time, by state and 
by age was obtained from the Behavioral Risk Factor Surveillance System (BRFSS).[11] 
Smoking prevalence data were available from 1955 onwards, and obesity prevalence data 
were available from 1970 onwards (Supporting material 3). We assumed smoking and 
obesity prevalence before these years to be equal to the 1955 and 1970 levels respectively. 
The relative risk of smokers versus non-smokers was estimated to be 1.6, and the relative 
risk for obese (body mass index ≥30) versus non-obese individuals was estimated to be 1.4.
[12-13] The prevalence of risk factors affected the risk for developing adenomas, 
subsequently an increase in risk factor prevalence would affect CRC incidence after an 
average lag time of approximately 20 years.[14]
The estimates for screening uptake over time were also obtained from BRFSS data 
(Supporting material 4).[11] We assumed no screening prior to 1978. For years in which no 
data were available, rates were extrapolated linearly. An overview of the test characteristics 
of screening tests used is provided in Supporting material 1.
The validity of the model has been tested previously using data from several large 
randomized screening and surveillance studies, such as the three large randomized 
controlled trials for fecal occult blood testing[8], the CoCap sigmoidoscopy study[15], and 
the National Polyp Study.[16] Additionally, the model was able to reproduce the observed 
CRC incidence and mortality trends in the US while accounting for secular trends in risk 
factor prevalence, screening practice, and chemotherapy treatment.[17]
Study Population
We used the model to simulate the Louisiana population from 1995 to 2009 (corrected for 
the impact of Hurricane Katrina) for both genders and all races combined. In a secondary 
analysis, we also simulated the black and white Louisiana populations separately. We did 
not analyze other racial groups or Hispanics separately due to small numbers in Louisiana. 
We restricted our analysis to the population aged 50 years and older, because this is the 
group for whom screening is recommended.[18-19]
Base case analysis
We simulated the Louisiana population with CRC risk factor prevalence, CRC screening 
uptake and stage-specific CRC relative survival as observed in Louisiana (Run 1). 
Alternatively, we modeled the Louisiana population assuming they had the same risk factors 
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(Run 2), screening (Run 3), CRC survival (Run 4), and a combination of all three (Run 5) as 
observed in New Jersey.
We did not incorporate all known risk factors for CRC into the model, because data were not 
available. Therefore the simulated CRC incidence (mortality) rates do not fully correspond 
with the observed rates in Louisiana in 2009. Instead, we assumed that the simulated relative 
benefit of New Jersey risk factors, screening and CRC survival over Louisiana would be 
applicable to the observed CRC incidence and mortality. This assumption seems reasonable; 
three randomized controlled trials on biennial guaiac FOBT screening found similar percent 
mortality reductions ranging from 15% to 21% despite being carried out in populations with 
a different background CRC incidence level.[20]
We calculated the expected CRC incidence (mortality) rates in Louisiana for the scenarios 
by applying the percent difference in age-standardized incidence (mortality) rates between 
Run 1 and Run 2, 3, 4, or 5, respectively, to the observed CRC incidence and mortality rates 
for Louisiana in 2009.
The observed excess CRC risk was calculated as the absolute difference in observed CRC 
incidence (mortality) rates between Louisiana and New Jersey in 2009 (Formula 1, 
Supporting material 5).[21] Subsequently, the expected excess risk from each of the 
modeled scenarios was calculated as the absolute difference between the expected CRC 
incidence (mortality) rate from each scenario and the observed incidence (mortality) in New 
Jersey (Formula 2-5, Supporting material 5).
Sensitivity analyses
We performed four sensitivity analyses. First we performed an analysis in which Louisiana 
residents not only received less screening but also lower quality screening, assuming 25% 
lower adenoma detection rates with endoscopy. We then re-estimated the reduction in excess 
CRC risk due to differences in screening assuming New Jersey screening adherence. 
Second, we explored the robustness of our results to the assumption that equal access to care 
resulted in the same stage-specific relative CRC survival for Louisiana and New Jersey by 
assuming that 25% of the difference in relative survival between states could not be taken 
away with equal access to care. Third, we evaluated the impact on mortality disparity if 
equal access to care not only resulted in the same stage-specific relative CRC survival for 
Louisiana as for New Jersey, but also in the same stage distribution. Finally, in the base case 
CRC relative survival estimates by state were estimated using SEER*Stat.[6] SEER*Stat 
uses US life tables to estimate expected mortality in the absence of cancer. Louisiana death 
rates are higher than overall US death rates, while New Jersey rates are lower. Therefore we 
performed a sensitivity analysis in which we corrected the CRC relative survival for the 
differential background mortality in each state.
Results
In 1995, the observed Louisiana CRC incidence rate (167 cases per 100,000 persons aged 50 
years and older) was approximately 19% lower than the New Jersey CRC incidence (205 
cases per 100,000) (Figure 1). By 2009 the ordering had reversed, with CRC incidence in 
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Louisiana being almost 10% higher than in New Jersey. For CRC mortality a similar pattern 
was observed (Figure 2). The observed excess in age-standardized CRC incidence and 
mortality rates in 2009 in Louisiana compared to New Jersey were 11.5 cases and 6.1 deaths 
per 100,000, respectively (Table 2 and 3).
If Louisiana had the same smoking and obesity prevalence as observed in New Jersey, the 
expected CRC incidence rate would have been 136.5 per 100,000 in 2009, 3.5% lower than 
the observed rate for Louisiana (Figure 1 and Table 2). The expected CRC mortality rate in 
2009 would have been 60.1 per 100,000 (3.0% lower than observed, Figure 2 and Table 3). 
In this scenario Louisiana would still have an excess of 6.5 cases and 4.3 deaths per 100,000 
compared to New Jersey.
If Louisiana would have had the same screening uptake or stage-specific relative CRC 
survival as New Jersey, CRC mortality would drop to 55.2 and 51.1 per 100,000 
respectively in 2009, 10.8% and 17.4% lower than the observed rate in Louisiana. With the 
same trends in smoking and obesity, screening, and stage-specific relative CRC survival as 
New Jersey combined, CRC mortality in Louisiana would have been 27.8% lower than the 
observed rate of 61.9 per 100,000 in Louisiana. In addition, this reversed the disparity 
between the states; Louisiana would have 13.6 cases and 11.1 deaths per 100,000 less as 
currently observed in New Jersey.
The observed disparity in CRC incidence and mortality between Louisiana and New Jersey 
was considerably higher for blacks (42.2 excess cases and 8.4 excess deaths per 100,000 
persons) compared to whites (0.5 excess cases and 1.2 excess deaths) (Tables 2 and 3). 
Interestingly, the potential reduction in CRC mortality if Louisiana had similar risk factor, 
screening and survival as New Jersey was lower for blacks than for whites; 18.3% and 
23.2%, respectively.
Sensitivity analyses
Our findings were robust for assumptions concerning quality of endoscopy, residual survival 
differences and stage distribution (Table 4). Lower-quality endoscopy slightly attenuated the 
potential reduction in excess mortality from 27.8% (base case) to 26.8%. Residual difference 
in stage-specific relative CRC survival and correcting for differential background mortality 
between Louisiana and New Jersey decreased the potential reduction in CRC mortality to 
24.0% and 25.0%, respectively. Stage distribution had virtually no effect.
Discussion
This study shows that removing differences in smoking and obesity prevalence, screening 
uptake, and stage-specific relative CRC survival would eliminate observed disparities in 
CRC incidence and mortality rates between Louisiana and New Jersey. Screening had the 
biggest impact on CRC incidence: the observed CRC incidence in Louisiana could be 
reduced by 15.2% by increasing CRC screening up to the level of New Jersey. Stage specific 
CRC relative survival had the largest impact on CRC mortality, the observed CRC mortality 
could be reduced by 17.4% by improving the survival to the level of New Jersey. 
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Eliminating differences in the prevalence of smoking and obesity had a relatively modest 
impact on CRC incidence (3.5% reduction) and mortality (3.0% reduction).
The reason that the impact of smoking and obesity is modest results from the relatively 
small impact of the individual risk factors on CRC incidence and mortality (relative risk of 
1.6 and 1.4 respectively) and the fact that the prevalence of these risk factors were similar 
between the two states (Supporting material 3).
Together, eliminating differences in risk factors, screening and survival not only completely 
eliminates the excess CRC incidence and mortality in Louisiana but reverses the pattern. 
This may sound surprising, but given that in the early 1990's New Jersey had higher 
incidence and mortality rates than Louisiana[2], it makes sense that the background CRC 
risk in Louisiana is actually lower than in New Jersey.
The disparity in CRC incidence and mortality rates between Louisiana and New Jersey 
mainly exists for blacks, and not for whites (Tables 2 and 3). When simply looking at the 
2009 rates, one could argue that the disparity between the two states is therefore a result of a 
difference in population distribution by race. However, when looking at the patterns since 
1995 it is clear that population distribution is not the explanation; for both races, the 
observed CRC incidence and mortality rates decreased less in Louisiana than in New Jersey. 
This finding is corroborated by our modeling, showing that CRC incidence and mortality 
rates in Louisiana could be reduced to a similar extent in blacks and whites if risk factors, 
screening and survival were the same as in New Jersey. Interestingly, the potential reduction 
was even somewhat higher in whites than in blacks. This finding is probably explained by 
the slight increase in CRC incidence and mortality in Louisiana blacks in the late 1990's, 
which cannot be explained by the factors investigated in this study. This means that other 
differences between Louisiana and New Jersey (e.g. other lifestyle factors such as red meat 
consumption or physical inactivity; gender differences or differences in proportion of 
Hispanic population) are contributing to the difference in CRC incidence and mortality 
between these two states. Consequently, some excess in CRC rates in blacks remained after 
removing differences in smoking, obesity, screening, and survival in Louisiana compared to 
New Jersey.
In our primary analysis, we considered screening uptake, assuming equal access to and 
quality of screening, between Louisiana and New Jersey. The lower population density and 
larger geographic area of Louisiana might make achieving equal access more difficult. In 
addition, quality of endoscopy has been shown to be dependent on the skill of the 
endoscopist performing the procedure, with colonoscopy being performed by 
gastroenterologists being more sensitive for cancer than colonoscopy by non-
gastroenterologists.[22] The number of certified gastroenterologists differs widely between 
states in the US. In Louisiana there were only 3.9 gastroenterologists per 100,000 residents 
in 2013 compared to 6.7 in New Jersey.[23] This pattern is mirrored in the other Southern 
and Northeastern states.[24]
Two limitations are noteworthy. First, we assumed that smoking and obesity prevalence 
only affected the risk for CRC by increasing adenoma incidence. This assumption is 
Lansdorp-Vogelaar et al. Page 6













supported by the similar relative risk of these risk factors for developing adenomas and 
CRC.[12-13] However, greater adenoma progression may also play a role in the increased 
risk. In that case, eliminating differences in risk factors will have a relatively larger impact 
on disparities in CRC rates, while eliminating differences in screening may have a smaller 
effect. Second, we have not explicitly considered state differences in treatment but used state 
differences in stage-specific relative CRC survival as a proxy. Data on use and quality of 
CRC treatment by state are sparse, especially for the population below 65 years old. One 
study suggested that Louisiana patients surgically treated for stage III colon cancer were 
significantly less likely to receive adjuvant chemotherapy than patients from other states.
[25] However, if part of the state differences in survival cannot be explained by differences 
in (the quality of) treatment, for example because Louisiana residents could have more 
comorbidities and are therefore unable to receive guideline therapy, we have overestimated 
the potential for reducing disparities in CRC mortality. We explored the impact of our 
assumption in a sensitivity analysis and found that the effect was limited.
The Patient Protection and Affordable Care Act (ACA, Pub.L. 111-148, 2010) may be an 
important step towards the reduction of health disparities between states although Louisiana 
has yet to expand the state Medicaid program. The ACA aims to improve access to quality 
health care for all Americans. Furthermore, all new health plans must cover certain 
preventive services including CRC screening without charging a deductible, co-pay or 
coinsurance. Several studies have shown that in situations with equal access to care, such as 
military medical centers, Department of Defense facilities or clinical trials, no differences in 
screening uptake or CRC treatments exist.[26-28] A notable example is universal CRC 
screening coverage in Delaware that eliminated the black-white disparities in CRC mortality 
rates.[29]
In conclusion, this study shows that the disparities in CRC incidence and mortality rates 
between Louisiana and New Jersey could be eliminated if Louisiana could attain New Jersey 
levels of risk factors, screening and CRC relative survival. Priority should be given to 
enabling Southern states to improve screening and survival rates.
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Age-standardized CRC incidence rates (per 100,000 individuals) in the 50+ year-old 
population from 1995-2009, as observed in Louisiana and New Jersey, and as expected in 
Louisiana if they would have had the same risk factors, and/or screening pattern as New 
Jersey.
Lansdorp-Vogelaar et al. Page 10














Age-standardized CRC mortality rates (per 100,000 individuals) in the 50+year old 
population from 1995-2009, as observed in Louisiana and New Jersey, and as expected in 
Louisiana if they would have had the same risk factors, screening pattern, and/or survival 
pattern as New Jersey.
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